Evolus, Inc. EOLS
6.63 USD -0.33 (-4.74%)
Regular-session close
6.63 0.00 0.00%
After hours · Nov 16, 4:26 PM ET
6.62 Day range 7.03
3.86 52-week range 9.31
- YTD
- -0.30%
- 1 year
- -8.17%
News
marketbeat.com Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows Evolus NASDAQ: EOLS executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027.
businesswire.com Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to…
benzinga.com Evolus Q3 2026 Earnings Call Transcript Evolus (NASDAQ:EOLS) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Evolus Affirms FY2026 Sales Guidance of $330.000M-$337.000M vs $334.100M Est Evolus (NASDAQ:EOLS) affirms FY2026 sales outlook from $330.000 million-$337.000 million to $330.000 million-$337.000 million vs $334.100 million estimate.
benzinga.com Evolus Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $78.000M Beat $77.662M Estimate Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 18.75 percent. This is a 72.73 percent decrease over losses of $(0.11)…
